The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

• Ages 18 to 65 years
• All sexes
• No healthy volunteers
• Adult, Older adult

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

About this study

Official title: The Effect of a Gamified Neuropathy Management Application on Cancer Behavior in Cancer Patients Undergoing Chemotherapy: A Prospective Follow-Up Study

Conditions

Cancer, Chemotherapy Induced Pain Neuropathy, Nursing, Gamification

Being tested

Gamified Neuropathy Management Application on Cancer Behavior

Keywords

cancer, chemotherapy induced pain neuropathy, nursing, gamification

Medical subject headings

Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

• Gamified Neuropathy Management Application on Cancer BehaviorBehavioural

  Also called intervention group

  The study will be conducted in three phases:

  Phase 1: The content of the gamified neuropathy management application used in the study will be prepared by the researchers using relevant literature.

  Phase 2: The developed gamified neuropathy management application will be introduced to patients during one-on-one interviews at the daytime chemotherapy clinic. After collecting pre-test data, the application will be sent to the patients, who will be asked to use it for 8 weeks.

  Phase 3: Following the start of the study's implementation, patients will be contacted in the 4th and 8th weeks to collect mid-study and post-test data.

What is being measured

The primary outcome is the main question the study is designed to answer.

1. The effect of gamified neuropathy management application on chemotherapy-associated peripheral neuropathic pain.

   DN4 Questionnaire: The DN4 pain questionnaire, developed by the French neuropathic pain group, is a questionnaire that includes symptoms and findings associated with neuropathic pain. The individual being evaluated answers the questions with yes or no. The total scale score is calculated by giving 1 point for each yes answer and 0 point for each no answer. In the scale, the cutoff value for neuropathic pain is determined as 4/10 and above. Turkish validity and reliability was determined by Unal-Çevik et al. It was made by and the Cronbach alpha coefficient was 0.97; The specificity and sensitivity in diagnosing neuropathic pain were found to be 96.6% and 95%, respectively.

   Measured: 6 months

2. The effect of gamified neuropathy management application on chemotherapy-associated peripheral neuropathic level

   CIPNAT, Tofthagen et al. (2011b). CIPNAT, which is a Likert type scale, consists of 2 parts. The first part consists of 36 items asking about symptom frequency, severity, and discomfort. In the second part, there are 14 items that evaluate which of the daily living activities peripheral neuropathy affects. First, patients are asked whether any of the nine symptoms developed after chemotherapy treatment. The frequency, severity and discomfort of the symptoms experienced after each question answered "Yes" are scored and evaluated with a 0-10 numerical rating scale. If the answer to the first 4 questions on the scale is "No", the other questions are not continued. These questions are the questions that determine whether there is the presence of CBPN (Kutlutürkan et al. 2017). A high score from the scale indicates that CBPN is high. The Turkish validity and reliability study of the scale was conducted by Kutlutürkan et al. (2017). The Cronbach alpha coefficient of the scale is 0.970.

   Measured: 6 months

3. The effect of gamified neuropathy management application on cancer behaviour

   Heitzmann et al. Developed by KSI-KV in 2011. This inventory is a 12-item unidimensional measurement tool designed to assess cancer patients' self-efficacy in coping. Each item of this 12-item scale is scored between 1-9. The scale score is calculated as the sum of all items. High scores from the scale indicate high self-efficacy for coping. The Cronbach alpha coefficient of this scale, which was evaluated on three sample groups, was found to be a = 0.84, a = 0.84, a = 0.88 for each sample, respectively. The construct validity of the scale was conducted using Exploratory Factor Analysis for the first sample, and four factors were obtained according to the results of the analysis: (1) Maintaining Independence and Positive Attitude; (2) Participating in Medical Care; (3) Coping and Stress Management; (4) Managing Affect. Adaptation of this scale to Turkish was made by İyigün et al. (2017).

   Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

1. First posted20 Dec 2024
2. Study start1 Jan 2025 (estimated)
3. Primary completion30 Aug 2025 (estimated)
4. Study completion31 Dec 2025 (estimated)

Resources

• Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
• Other trials for CancerStudies of the same condition, open and under way.
• More trials run by Ankara Yildirim Beyazıt UniversityThe sponsor's other registered studies.
• What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.